The persistent promise of combining HGF/MET and EGFR inhibition in non‐small cell lung cancer

The persistent promise of combining HGF/MET and EGFR inhibition in non‐small cell lung cancer

Hepatocyte growth factor/mesenchymal‐epidermal transition factor (MET) dysregulation is a viable target in non‐small cell lung cancer, both alone and potentially in combination with epidermal growth factor receptor inhibition. Future trials involving epidermal growth factor receptor and MET inhibito...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2017-08, Vol.123 (15), p.2798-2801
Hauptverfasser: Chuang, Jody C., Neal, Joel W.
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies, Monoclonal
c-Met protein
Cancer
Carcinoma, Non-Small-Cell Lung
Clinical trials
Epidermal growth factor
Epidermal growth factor receptors
ErbB Receptors
Erlotinib Hydrochloride
Hepatocyte Growth Factor
Humans
Inhibition
Inhibitors
Lung cancer
Lung Neoplasms
Mesenchyme
Non-small cell lung carcinoma
Populations
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hepatocyte growth factor/mesenchymal‐epidermal transition factor (MET) dysregulation is a viable target in non‐small cell lung cancer, both alone and potentially in combination with epidermal growth factor receptor inhibition. Future trials involving epidermal growth factor receptor and MET inhibitors should focus on more selected patient populations and include relevant biomarker studies. See also pages 2936‐44.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.30718